Patent intelligence · US
US 11413301
Composition comprising sea cucumber extract as effective ingredient for preventing and treating Bruch's membrane dysfunction-related disease
Composition comprising sea cucumber extract as effective ingredient for preventing and treating Bruch's membrane dysfunction-related disease
Patent details — US 11413301
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 16, 2022
- Expiration
- Aug 11, 2042
- Applicant
- Altregen Co., Ltd.
- Claims
- 15
- CPC classes
- A61K, A61K31/704, A61K31/7048, A61K35/616
Quick answer
US 11413301 (Composition comprising sea cucumber extract as effective ingredient for preventing and treating Bruch's membrane dysfunction-related disease) is held by Altregen Co., Ltd.. Status: granted. Granted Aug 16, 2022. Expires Aug 11, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Altregen Co., Ltd.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/704, A61K31/7048, A61K35/616, A61P, A61P27/02
More from Altregen Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11413301?
US 11413301 (Composition comprising sea cucumber extract as effective ingredient for preventing and treating Bruch's membrane dysfunction-related disease) is held by Altregen Co., Ltd.. Status: granted. Granted Aug 16, 2022. Expires Aug 11, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11413301?
Altregen Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11413301 expire?
Our index shows an expiration date of Aug 11, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.